- Home
- OLN vs IONS Comparison
OLN vs IONS Comparison
Compare OLN & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLN
- IONS
- Stock Information
- Founded
- OLN 1892
- IONS 1989
- Country
- OLN United States
- IONS United States
- Employees
- OLN N/A
- IONS N/A
- Industry
- OLN Major Chemicals
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- OLN Industrials
- IONS Health Care
- Exchange
- OLN Nasdaq
- IONS Nasdaq
- Market Cap
- OLN 5.7B
- IONS 6.0B
- IPO Year
- OLN N/A
- IONS 1991
- Fundamental
- Price
- OLN $41.46
- IONS $36.95
- Analyst Decision
- OLN Buy
- IONS Buy
- Analyst Count
- OLN 15
- IONS 18
- Target Price
- OLN $53.40
- IONS $62.00
- AVG Volume (30 Days)
- OLN 1.8M
- IONS 1.1M
- Earning Date
- OLN 10-24-2024
- IONS 11-06-2024
- Dividend Yield
- OLN 1.92%
- IONS N/A
- EPS Growth
- OLN N/A
- IONS N/A
- EPS
- OLN 1.24
- IONS N/A
- Revenue
- OLN $6,483,400,000.00
- IONS $803,067,000.00
- Revenue This Year
- OLN N/A
- IONS N/A
- Revenue Next Year
- OLN $6.30
- IONS $16.31
- P/E Ratio
- OLN $33.68
- IONS N/A
- Revenue Growth
- OLN N/A
- IONS 30.57
- 52 Week Low
- OLN $39.47
- IONS $35.95
- 52 Week High
- OLN $60.60
- IONS $54.44
- Technical
- Relative Strength Index (RSI)
- OLN 42.85
- IONS 39.33
- Support Level
- OLN $41.84
- IONS $37.18
- Resistance Level
- OLN $44.76
- IONS $40.07
- Average True Range (ATR)
- OLN 1.12
- IONS 1.19
- MACD
- OLN 0.10
- IONS -0.02
- Stochastic Oscillator
- OLN 41.29
- IONS 10.74
About OLN Olin Corporation
Olin Corp manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on the product type. The Chlor alkali products and Vinyls segment, which generates the majority of revenue, sells chlorine and caustic soda, which are used in a variety of industries including cosmetics, textiles, crop protection, and fire protection products. The Epoxy segment sells epoxy resins used in paints and coatings. The Winchester segment sells sporting ammunition and ammunition accessories under the Winchester brand. The majority of revenue comes from the United States.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.